Testosterone Therapy for Hypogonadism Not Tied to Increased CV Risk
No evidence of increase seen for short- to medium-term cardiovascular risk, but data lacking regarding long-term safety
Diagnosis & Disease Information
Morbid Obesity Ups Odds of Multiple Urologic Conditions
Efforts to reduce obesity may cut the prevalence of these urological conditions.
FDA Approves Oral Testosterone Replacement Therapy Tlando
The approval was based on data from a phase 3 study that evaluated the efficacy and safety of Tlando in 95 adult hypogonadal male patients.
Cardiovascular Events, VTE Tied to Polycythemia During Testosterone Therapy
Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism.
Testosterone Therapy for Hypogonadism May Cut Risk for CV Events
Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors
COVID-19 Is Associated With Low Testosterone in Men
Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.
e-ECE: Testosterone Therapy Mitigates NAFLD in Obese Men With FH, T2D
Testosterone undecanoate therapy reduces NAFLD grade in obese men with functional hypogonadism and type 2 diabetes
Severe COVID-19 Associated With Low Testosterone in Men
It is unclear whether low testosterone is a marker or a mediator of severe and impending severe COVID-19 illness.
Inflammatory Diet May Contribute to Testosterone Deficiency in Men
Each 1 unit increment in Dietary Inflammatory Index was associated with a 4.0% increase in the odds of testosterone deficiency.
Kyzatrex Under Review for Primary and Secondary Male Hypogonadism
Kyzatrex is an investigational, oral testosterone undecanoate softgel that utilizes lymphatic absorption and phytosterols to increase bioavailability and provide a favorable pharmacokinetic profile.
- Loading...
Loading...
Next post in Hypogonadism
Loading... 
Loading...